Vai offline con l'app Player FM !
The World in a Grain of Sand: BioAge
Manage episode 455156678 series 3526488
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss BioAge, a longevity biotech with a pipeline of therapies for diseases of aging including cardiometabolic disease and neuroinflammation. Please note that this episode was recorded before the clinical readout of BioAge's apelin receptor agonist Azelaprag.
We dive into:
- BioAge's founding by first-time biotech entrepreneur Kristen Fortnoy as a Stanford spinout analyzing aging-related biomarkers
- Their pivot from platform to asset in-licensing, securing Azelaprog from Amgen after discovering its potential in obesity when combined with GLP-1 drugs
- Their clinical strategy running combination trials with both Lilly's Zepbound and Novo's Wegovy, supported by a strategic supply agreement giving Lilly first negotiation rights
- A dramatic survival story of navigating near-death in 2022-2023 through bridge financing
14 episodi
Manage episode 455156678 series 3526488
KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss BioAge, a longevity biotech with a pipeline of therapies for diseases of aging including cardiometabolic disease and neuroinflammation. Please note that this episode was recorded before the clinical readout of BioAge's apelin receptor agonist Azelaprag.
We dive into:
- BioAge's founding by first-time biotech entrepreneur Kristen Fortnoy as a Stanford spinout analyzing aging-related biomarkers
- Their pivot from platform to asset in-licensing, securing Azelaprog from Amgen after discovering its potential in obesity when combined with GLP-1 drugs
- Their clinical strategy running combination trials with both Lilly's Zepbound and Novo's Wegovy, supported by a strategic supply agreement giving Lilly first negotiation rights
- A dramatic survival story of navigating near-death in 2022-2023 through bridge financing
14 episodi
Tutti gli episodi
×Benvenuto su Player FM!
Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.